Weill Cornell Medicine received a five-year, $5 million grant from the National Cancer Institute to develop innovative support strategies for an understudied group of cancer patients: adolescents and young adults.
Targeting tumor-specific inflammatory processes in colorectal cancer could enhance the efficacy of some anticancer therapies and prevent drug resistance, Weill Cornell researchers have found.